Systemic lupus erythematosus is a complex autoimmune disorder characterized by the production of pathogenic anti-nuclear antibodies. Previous work from our laboratory has shown that the introgression of a New Zealand Black-derived chromosome 4 interval onto a lupus-prone background suppresses the disease. Interestingly, the same genetic interval promoted the expansion of both Natural Killer T-and CD5 + B cells in suppressed mice. In this study, we show that ablation of NKT cells with a CD1d knockout had no impact on either the suppression of lupus or the expansion of CD5 + B cells. On the other hand, suppressed mice had an expanded population of IL-10-producing B cells that predominantly localized to the CD5 + CD1d low compartment. The expansion of CD5 + B cells negatively correlated with the frequency of pro-inflammatory IL-17 A-producing T-cells and kidney damage. Adoptive transfer with a single injection of total B cells with an enriched CD5 + compartment reduced the frequency of memory/activated, IFNγ-producing, and IL-17 A-producing CD4 T-cells but did not significantly reduce autoantibody levels. Taken together, these data suggest that the expansion of CD5 + IL-10-producing B cells and not NKT cells protects against lupus in these mice, by limiting the expansion of pro-inflammatory IL-17 A-and IFNγ-producing CD4 T-cells.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by the production of pathogenic antinuclear autoantibodies (ANA). Previous murine studies indicate that SLE is a complex genetic disease, in which development of disease reflects the balance between susceptibility and suppressor loci. Although studies of congenic mouse strains with introgressed homozygous intervals derived from lupus-prone mouse strains have provided considerable insight into how susceptibility loci promote disease development, less is known regarding the mechanisms involved in inhibition of autoimmunity by suppressor loci. Our laboratory has previously shown that introgression of a New Zealand Black (NZB) homozygous chromosome (c) 4 interval (B6.NZBc4), spanning 32-150 Mb, onto a C57BL/6 (B6) congenic mouse strain with a homozygous NZB c1 interval (B6.NZBc1) significantly attenuated the fatal autoimmunity observed in this mouse strain (B6.NZBc1c4), 1, 2 indicating the presence of a suppressor locus on NZB c4. 3 Examination of the immune system in B6.NZBc4 mice revealed expansion of two innate-like lymphocyte populations, invariant Natural Killer T (NKT) cells and CD5 + B cells, leading us to hypothesize that one or both of these populations inhibit autoimmunity in B6.NZBc1c4 bicongenic mice. This conjecture was based on studies showing that the number and/or activation of NKT cells, invariant-like cells that recognize glycolipids presented on CD1d can modulate autoimmune responses. However, the exact role of NKT cells in autoimmunity remains somewhat contentious, with opposing roles identified in different models of disease. For example, in the (NZB x New Zealand White (NZW))F 1 mouse model of SLE, activation of NKT cells by injection of αGalCer exacerbated autoimmunity by induction of a Th1 response that promoted production of pathogenic IgG2a autoantibodies. 4 Supporting a role for these cells in augmenting disease, invariant NKT cells have also been shown to directly interact with autoreactive B cells to promote autoantibody production. 5, 6 In contrast, production of autoantibodies was increased in the absence of NKT cells in a similar model of SLE, suggesting that these cells may sometimes limit rather than enhance the autoimmune response. 7 Studies on SLE patients have also revealed defects in NKT cell number and function, suggesting a link to disease progression. 8 In addition to NKT cells, the innate CD5 + B-cell population has also been shown to play a regulatory role in autoimmunity. This followed the discovery that a subset of these cells, that produces IL-10, can inhibit autoimmune disease. These newly defined regulatory cells, termed B10 or Breg, have been shown to express a number of cellular markers, but generally localize to the CD5 + CD1d high B-cell compartment. 9 There has been disparity in the literature regarding both the ontogeny and phenotypic profile of Breg cells, 10, 11 with numerous studies showing an essential role for IL-10 in the suppressive ability of these cells. 12 Although IL-10 is a pleiotropic cytokine that has numerous effects on different immune populations, suppression of autoimmunity by IL-10 is usually mediated through the inhibition of dendritic cell maturation and antigen presentation or by direct effects on T-cell proliferation and differentiation. 13 In recent years, several groups have identified populations of IL-10-producing B cells in various autoimmune mouse models with the capacity to inhibit disease through suppression of proinflammatory T-cells. In mouse models of colitis, the transfer of peritoneal IL-10-producing B10 cells was shown to reduce disease severity by suppressing CD4 T-cell activation and cytokine secretion. 14 Similarly, in a collagen-induced model of arthritis, IL-10 production by B cells was shown to be critical to suppressing Th1 and Th17 responses and attenuating disease. 15, 16 These findings contrast with a study in the MRL.lpr mouse model of SLE, where IL-10 deletion in B cells was shown to have no effect on disease. 17 Although these results might suggest that regulatory B cells do not have a role in lupus, an a emerging body of research supports the role of IL-10-producing B cells in controlling systemic autoimmunity. [18] [19] [20] [21] This research also extends to SLE patient studies, which have demonstrated that altered Breg function may contribute to lupus pathogenesis in humans. [22] [23] [24] [25] [26] In this study, we have sought to determine the suppressive capacity of the expanded NKT and CD5 + B-cell populations in our congenic mouse models. Through knockout of NKT cells, we show that NKT cells are dispensable for the inhibition of autoimmunity in B6.NZBc1c4 bicongenic mice. In contrast, the expanded CD5 + B-cell population in these mice was shown to be highly IL-10 competent and the size of this population correlated with suppression of autoimmunity in NZB.c1c4 mice. Using an adoptive transfer model, we show that these B cells appear to act by inhibition of activation and expansion of pro-inflammatory Th1 and Th17 subsets. Our results suggest Breg cells have a similar role in lupus to other autoimmune diseases and may attenuate disease by limiting T-cell help for pathogenic autoantibody production.
RESULTS
NKT cells do not suppress autoimmunity in B6.NZBc1c4 mice Previous work from our laboratory showed that B6.NZBc1c4 mice exhibit a marked decrease in autoantibodies, reduced kidney damage and greater survival as compared with B6.NZBc1 mice. 3 These suppressed B6.NZBc1c4 mice retained the same expansion of CD5 + B cells and NKT cells as B6.NZBc4 mice. Given that other groups have shown a regulatory and suppressive role for NKT cells in SLE models, we initially hypothesized that this expansion was acting to protect suppressed mice from fatal autoimmunity.
To evaluate the role of NKT cells in the observed suppression, B6.NZBc1c4.CD1d − / − mice were generated. Mice that lacked a functional CD1d gene had no NKT (PBS57 Tetramer + TCRβ + ) cells (Figure 1a ), whereas heterozygous B6.NZBc1c4.CD1d − /+ mice did not have statistically different frequencies of splenic NKT cells as compared with CD1d-sufficient controls. Notably, the CD1d knockout did not affect the proportion of CD5+ B cells ( Supplementary Figure 1) . To assess the impact of CD1d gene deletion on the severity of autoimmunity, mice were aged to 8-9 months and their autoantibody levels and kidney damage examined. As we had previously observed, the levels of IgG anti-ssDNA and -dsDNA, but not anti-chromatin Abs, were significantly reduced in B6.NZBc1c4 mice as compared with B6.NZBc1 mice, and this resulted predominantly from reduced production of IgG2a auto-Abs. Interestingly, the CD1d knockout had a limited impact on the suppression of auto-Ab production in B6.NZBc1c4 mice ( Figure 1b ). Indeed, B6.NZBc1c4.CD1d − / − mice had significantly lower levels of anti-chromatin IgG and IgG2a autoantibodies when compared with wild-type B6.NZBc1c4 mice, suggesting that NKT cells may be acting to promote rather than suppress autoimmunity in B6.NZBc1c4 mice.
In contrast to our previous study, there was no reduction in kidney scores seen in 8-month-old B6.NZBc1c4 as compared with B6.NZBc1 mice. In our previous study,~30% of the B6.NZBc1c4 mice had reduced numbers of B cells, a phenotype that was not observed in the current study. As these mice had the most attenuated kidney disease, the lack of differences observed in this study may be due to the lack of mice with this phenotype. Nevertheless, as further evidence of a lack of role of NKT cells in disease suppression, the light microscopy kidney scores of B6. NZBc1c4.CD1d -/did not differ significantly from B6.NZBc1c4 CD1d-sufficient mice ( Figure 1d ). Survival in B6.NZBc1c4.CD1d -/mice was also not reduced (data not shown).
B6.NZBc4 and B6.NZBc1c4 mice have expansions of IL-10producing B cells that localize to the CD5 + B-cell compartment We next examined whether the expanded CD5 + B-cell population in B6.NZBc4 and B6.NZBc1c4 mice could have a regulatory function. To address this possibility, we began by investigating whether there were increased proportions of IL-10-secreting B cells in these mouse strains. Splenocytes were stimulated with the same combination of lipopolysccharides (LPS), phorbol 12-myristate 13-acetate (PMA), and Ionomycin that had been used in previous studies to assess Breg numbers/function, 27 and the frequencies of IL-10-producing B cells were quantified by flow cytometry (Figures 2a-c ). This revealed that B6.NZBc4 and B6. NZBc1c4 mice had a~1.5-2-fold expansion of splenic IL-10producing B cells as compared with B6 and B6.NZBc1 mice ( Figure 2c ).
Other groups have shown that Breg cells primarily localize to the CD5 + CD1d high or the T2-MZP compartments. 12 We therefore examined expression of CD1d and CD5 on the IL-10-producing B cells (Figures 2d-h ). In B6.NZBc4 and B6.NZBc1c4 mice, the predominant increase in IL-10-producing cells was found primarily in the expanded CD5 + compartment (Figures 2e and f ). Within the CD5 + compartment, the majority of the expansion of IL-10producing cells appeared to arise from increases in the CD5 + CD1d low population ( Figure 2g ). Interestingly, the frequency of traditional B10 regulatory cells, which localize to the CD1d high CD5 + B-cell compartment, was only slightly increased in B6. NZBc1c4 mice ( Figure 2h ). We also assessed for differences in the levels of IL-10 produced in the gated compartments by examining the MFI for IL-10 staining. Importantly, there were no differences between the congenic strains for any of the populations examined or between the CD5 + CD1d low and CD5 + CD1d high compartments within each mouse strain (data not shown). To determine whether the increase in IL-10 + B cells in B6.NZBc1c4 mice was simply due to an expansion of their splenic CD5 + compartment, we measured the frequency of IL-10-producing cells as a proportion of the expanded CD5 + pool (Figure 2i ). By using this measure, we noted that B6.NZBc1c4 mice had a significant expansion of IL-10producing cells within the CD5 + compartment, whereas the proportion of these cells was similar in B6 and B6.NZBc4 mice. These results suggest that CD5 + B cells are expanded genetically by a locus on chromosome 4, but further driven to produce IL-10 in the context of the autoimmune environment in B6. NZBc1c4 mice.
Phenotypic and functional characterization of the expanded IL-10producing population in B6.NZBc4 mice To better characterize the expanded IL-10-producing pool, we tested the expression of several cell-surface markers that discriminate between various B-cell populations. Expression of these markers on IL-10-producing B cells, gated as in Figure 2 , was compared between strains ( Supplementary Figure 2) . Although there was heterogeneity in the cell-surface molecules expressed by these cells, a considerable proportion expressed typical B1a makers including higher CD43, low IgD, and low B220 levels. Given the recent identification of suppressive IL-10 producing plasmablasts in mice and humans, 28, 29 we also sought to identify this population in our congenic strains. As shown in Supplementary  Figure 3 , the plasmablast population was not expanded in 4-month-old B6.NZBc1c4 mice. Although there was a CD138 sub-population that produced IL-10 that was significantly expanded in B6.NZBc1c4 mice, this sub-population accounted for only~1 percent of the total IL-10 B-cell population.
Next, we investigated the ability of SLE-related TLR ligands and nuclear antigens to stimulate IL-10 production in CD5 + B cells ( Supplementary Figure 4) . Interestingly, CD5 + B cells from both B6 and B6.NZBc4 mice could produce IL-10 when stimulated with a number of TLR agonists and nuclear auto-antigens. Although not significantly different, CD5 + B cells from B6.NZBc4 mice did demonstrate a trend toward higher IL-10 production following a stimulation with PolyI:C, histone and chromatin. This finding suggests that the expanded CD5 + population in B6.NZBc4 mice may be more prone to secrete large quantities of IL-10 in response to nuclear auto-antigens, supporting a potential role in the suppression of lupus-like autoimmunity.
Expansion of regulatory B cells is associated with a reduced frequency of pro-inflammatory CD4 T-cells in suppressed B6. NZBc1c4 mice
We have previously shown that B6.NZBc1 mice have increased proportions of Th1 and Th17 CD4 cells, which appear to have an important role in disease progression. Analysis of splenic frequencies of these two cell subsets revealed that 4-month-old B6.NZBc1, but not B6.NZBc1c4 mice had clearly elevated levels of Th1 and Th17 cells (Figures 3b-c). At 8 months of age, there was an inverse correlation between the levels of IL-17A-and IFNγproducing CD4 T-cells and the levels of pathogenic anti-dsDNA IgG2a autoantibodies in B6.NZBc1c4 mice (Figures 3d and e ), raising the possibility that inhibition of expansion of these proinflammatory subsets limits autoantibody production. In support of a regulatory role for CD5 + B cells in the reduced expansion of pro-inflammatory T-cell subsets in B6.NZBc1c4 mice, expansion of CD5 + B cells was negatively correlated with the proportion of IL-17 A-producing cells in 8-month-old mice (Figure 3f ). More telling was the finding that the frequency of IL-10-producing B cells negatively correlated to the light microscopy kidney score ( Figure 3g ).
Recent work in other mouse models has shown that regulatory B cells may exert their function by expanding T regulatory cells in a glucocorticoid-induced TNFR-related protein (GITR)-dependent manner. 30 To address this possibility, the frequency of functional (CD25 + ) regulatory cells was measured in our mice. At four months of age, there were no differences in the frequency of functional T regulatory cells across all mouse strains (Figures 4a and b) . Interestingly, the frequency of CD25 − T regulatory cells was significantly expanded in B6.NZBc1 mice with B6.NZBc1c4 mice showing intermediate levels (Figure 4c ). This population of cells may represent a reservoir of inactive or non-functional but committed T regulatory cells. 31, 32 Thus, the expansion of these cells in B6.NZBc1 mice may represent the byproduct of excessive immune activation, which is reduced in suppressed B6.NZBc1c4. More importantly, when frequencies of IL-10-producing B cells and functional T regulatory cells were compared, there was no correlation between the two groups of regulatory cells, supporting the disassociation of these two populations (Figure 4d ).
Transfer of B cells from B6.NZBc4 but not B6 mice reduces the frequency of pro-inflammatory T-cell populations in autoimmune B6.NZBc1 mice To further explore the possibility that the expansion of IL-10producing CD5 + B cells, associated with the NZB c4 interval, suppresses autoimmunity in B6.NZBc1c4 mice, we used an adoptive transfer approach. 8-10 million total B cells from B6 or B6.NZBc4 mice were transferred into 2-month-old autoimmuneprone B6.NZBc1.Thy1 a IgH a recipients and their impact on autoantibody levels and expansion of pro-inflammatory T-cell subsets assessed 2 months later. As shown in Supplementary Figure 5 , very few of the transferred B cells were still present 2 months following transfer, with no difference observed between transferred B6 and B6.NZBc4 cells in the number of surviving cells. For both transferred B-cell populations, the majority of remaining B cells were CD5and IL-10 -, with slightly higher proportions of transferred B6.NZBc4 cells being CD21 hi . Analysis of anti-ssDNA and -dsDNA antibody production in recipient mice revealed generally low levels of autoantibodies with no significant differences between those that received B6 or B6.NZBc4 B cells (Figure 5a ). In contrast, there was a clear reduction in the frequency of memory/active CD44 hi CD62L − , and IFNγ + and IL-17 A-producing CD4 T-cells (Figures 5c, e and f) in recipient mice that had received B6.NZBc4 as compared with B6 B cells. To investigate whether the CD5 + cells in the transferred B cells were responsible for this decrease, we transferred 1 million cell-sorted CD5 + B cells or 10 million CD5-depleted B cells from B6.NZBc4 mice into B6. NZBc1 recipient mice. These numbers of cells were chosen to mimic the numbers of cells for each population that were present in the total B cell transfers. Following transfer of CD5 + B cells there was a trend toward decreased frequencies of memory/active and IFNγ producing CD4 T-cells but not IL-17 A-producing CD4 T-cells, as compared with mice receiving CD5 − B cells. (Figures 5g-i ).
DISCUSSION
In this study, we have shown that the expansion of IL-10producing CD5 + B cells in B6.NZBc1c4 mice is associated with protection against spontaneous lupus-like autoimmunity and decreased frequencies of pro-inflammatory Th1 and Th17 cells. Consistent with the possibility that IL-10-producing CD5 + cells limit expansion of pro-inflammatory T-cell subsets in these mice, adoptive transfer of B cells from B6.NZBc4 mice into autoimmune B6.NZBc1 recipients lowered the frequency of Th1 and Th17 cells. However, transfer of B cells from B6.NZBc4 mice failed to reduce the production of autoantibodies or kidney damage (data not shown) in 4-month-old recipient mice. Nevertheless, studies in aged B6.NZBc1c4 mice showed a clear inverse correlation between the frequencies of CD5 + or IL-10-producing B cells and the frequency of pro-inflammatory T-cell populations and disease severity, suggesting that these cells may also act to suppress autoantibody production. To our knowledge, this is the first time that an expansion of regulatory CD5 + B cells has been identified in a spontaneous mouse model of SLE.
Given the increase in splenic NKT cell frequencies observed in suppressed B6.NZBc1c4 mice, we investigated their relative role in disease progression through generation of CD1d knockouts that lack NKT cells. Although NKT cells can act to rapidly secrete large quantities of cytokine and have been shown in multiple autoimmune models to modulate the autoimmune response, their absence had little or no impact on the severity/progression of autoimmune disease in our mice. This finding suggests that genetically-derived concurrent immune defects may override the relative importance of NKT cells in our model. In support of this concept, NKT cells from B6.NZBc1c4 mice demonstrate impaired function following stimulation with the prototypic ligand, αGalCer (unpublished observation), which we have localized to the parental B6.NZBc1 strain. Thus, the lack of effect of NKT cell deletion on the disease course in our mice, despite the expansion of this population, may reflect the fact that NKT cell function is already impaired. Importantly, the loss of NKT cells had no impact on the expansion of CD5 + B cells or the proportion of IL-10producing B cells in our mice, and clearly did not abrogate the suppression seen in these mice.
Recent literature has provided evidence for a heterogeneous population of CD5 + IL-10-producing B cells capable of controlling various autoimmune responses. 33 In our mice, we found an expansion of this population that localized to chromosome 4. Contrary to the established literature, the expansion of CD5 + IL-10producing B cells in our mice was predominantly located within the CD1d low compartment rather than the CD1d high compartment of typical B10 cells. Using various stimuli, we showed that splenic CD5 + B cells could secrete IL-10 in response to a number of SLErelated TLR ligands and nuclear auto-antigens. This finding may explain the capacity of this population to suppress disease in lupus-prone B6.NZBc1c4 mice, where the autoimmune response is specifically focused upon nuclear antigens. Notably, the proportion of IL-10-producing CD5 + B cells was increased in B6.NZBc1c4 as compared with B6.NZBc4 mice, raising the possibility that these cells are being recruited or activated in response to the autoimmune processes initiated by the NZB chromosome 1 interval. Similar correlations have been shown in SLE patients, with increased levels of circulating regulatory B cells reported during disease flares. 34 Taken together, these findings suggest that stochastic expansion or generation of CD5 + B cells may occur through stimulation with auto-antigens.
Several other groups have produced and/or characterized mice with NZB chromosome 4 intervals. An overlapping interval from New Zealand Mixed (NZM) mice, comprised of NZB-derived genetic material, has been shown to promote the expansion of splenic and peritoneal B1a cells. However, in contrast to our results, these studies characterized this expansion as proinflammatory. 35, 36 The origin of this difference likely arises from the difference in the length of the NZB interval between the NZMderived congenic interval and the NZB interval in our mice, which contains an additional, more centromeric NZB genetic region. This proposition is supported by the observation that groups working on NZM-derived chromosome 4 congenic mice have never reported an expansion of NKT cells or an increase in IL-10producing B cells. 35 Thus, our larger chromosome 4 congenic interval, which is purely NZB derived, may contain additional genetic defects that separately drive either the expansion of NKT cells or the production of IL-10-secreting B cells, and which are responsible for the suppression observed in our bicongenic mice. In unpublished observations, we have narrowed both of these expansions to an NZB-derived region spanning 91-123 Mb of chromosome 4. Notably, within this interval is a second NZBderived genetic locus that has been shown to lead to reduced receptor editing of DNA-reactive B cells. 37 It is possible that this locus leads to an increased proportion of nuclear-antigen reactive B1 cells in B6.NZBc4 mice that could enhance their ability to regulate lupus-like autoimmunity.
The expansion of pro-inflammatory Th1 and Th17 cells has been well documented to have a significant role in SLE pathogenesis. [38] [39] [40] Studies have shown that these cell types support autoantibody production and can directly cause damage by infiltrating into kidneys. 41 In our bicongenic B6.NZBc1c4 mice, at 8 months of age the expansion of CD5 + B cells negatively correlated with the frequency of IL-17 A-producing CD4 T-cells and kidney damage. This finding suggests that CD5 + IL-10producing cells may act to prevent the expansion of proinflammatory T-cell subsets and thereby limit autoantibody generation and kidney disease.
To validate the suppressive role of the CD5 + expansion in B6. NZBc1c4 mice, we transferred total and sorted CD5 + B cells into autoimmune-prone mice. Although we could not detect any changes in autoantibody levels or kidney damage, we did notice a striking decrease in the levels of memory/activated, Th1, and Th17 CD4 T-cell subsets upon transfer of total B cells from B6.NZBc4 mice. Transfer of cell-sorted CD5 + B cells from B6.NZBc4 mice resulted in a similar trend for memory/activated and Th1 but not Th17 CD4 T-cells. The absence of differences in autoantibody titers or kidney damage after transfer of total B cells may reflect a need to perform multiple injections. From our survival data, it is clear that at 2 months post-injection, transferred CD5 + B cells can no longer be identified in the spleen of recipient mice ( Supplementary Figure 4) . Simply put, at this time point the cells may be exhausted or depleted and unable to continue to control autoimmunity. Other groups have shown similar findings with GFP transgenic mice, showing that regulatory B cells only transiently express IL-10. 42 An alternative possibility is that the mice did not have enough time to produce sufficiently high autoantibody levels to detect differences. Although we did not directly examine the mechanisms by which the B6.NZNc4 B cells prevent expansion of proinflammatory T-cell subsets and regulate autoimmunity, it is unlikely that this occurs as the result of expansion of regulatory T-cells, as has been suggested by some groups. 30 The proportion and number of T regulatory cells were unaffected by the expansion of IL-10-producing CD5 + cells in B6.NZBc1c4 mice, which had lower levels of Foxp3-expressing cells when compared with parental B6.NZBc1 controls. We were not able to address whether IL-10 secretion plays a role in limiting pro-inflammatory T-cell expansion in recipient mice, because knockout of IL-10 in B6. NZBc4 mice affected not only IL-10 secretion, but also normalized the CD5 + B-cell expansion (unpublished observations).
In summary, we conclude that the expanded NZB chromosome 4-derived CD5 + B-cell population is not pro-inflammatory, but instead likely has a regulatory phenotype. Activation of this population in an autoimmune context may lead to suppression of autoimmunity by inhibiting pro-inflammatory T-cell subsets that have an important role in the production of pathogenic antinuclear antibodies.
MATERIALS AND METHODS

Ethics statement
Mice were housed in a Canadian Council on Animal Care approved facility at the Toronto Western Research Institute, part of the University Health Network. All experiments performed in this study were approved by the Animal Care Committee of the University Health Network (Animal Use Protocol 123). Mice B6 and NZB mice were purchased from Taconic (Germantown, NY, USA) and Harlan Sprague Dawley (Blackthorn, England), respectively. Congenic mice were generated as previously described. 3 B6.CD1d − / − and B6.Thy1 a IgH a mice were originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and bred onto the various congenic backgrounds, using primer assisted breeding. Only female mice were used for experiments in this study.
Flow cytometry and cell sorting
Splenocytes were harvested and RBC removed, as previously described. 3 Half a million cells were incubated with mouse IgG (Sigma-Aldrich, St Louis, MO, USA) for 15 min on ice prior to staining with various combinations of directly conjugated mAbs for 30 min on ice. The following antibodies were used for primary staining (all purchased from BioLegend, San Diego, CA, USA or BD Biosciences, San Jose, CA, USA): FITC-conjugated anti-TCRβ (H57-597), -CD3ε(145-2C11), -CD1d(1B1), -CD62L(MEL-14), -CD23(B3B4), -IgM a (MA-69), -CD44(1M7), and -CD4(GK1.5); PE-conjugated anti-NK1.1 (PK136), -CD24(M1/69), -CD5(53-7.3), -CD44(1M7), -IgM b (AF6-78), and -B220 (RA3-6B2); PE-Cy7 anti-CD19(6D5), -CD8(53-6.7), -CD138(MI15) and -CD44 (1M7); PerCP-CY5.5 conjugated anti-CD3ε(145-2C11) and -CD4(GK1.5); Allophycocyanin-conjugated anti-CD21(7E9), -CD19(6D5), -CD5(53-7.3) and -CD25(3C7); BV605 conjugated anti-B220(RA3-6B2) and -CD3 ε(145-2C11); Pacific Blue-conjugated anti-CD4(GK1.5) and -B220(RA3-6B2); Biotinconjugated anti-NK1.1(PK136) and -CD19(6D5). Allophycocyanin-, PerCP-CY5.5-, Pacific Blue-or Allophycocyanin-Cy7-conjugated streptavidin, purchased from BioLegend, was used for secondary staining of biotinylated mAbs. Dead cells were identified by staining with 0.6 μg ml − 1 Propidium Iodide (Sigma-Aldrich). Allophycocyanin-conjugated unloaded and PBS-57loaded mouse CD1d tetramers were generously provided by the National Institutes of Health Tetramer Core Facility (Atlanta, GA, USA). Events were collected on a BD LSRII or BD FACSCanto and analyzed using FlowJo software (Tree Star Inc., Ashland, OR, USA).
T regulatory (Treg) cell staining
For Treg staining, RBC-depleted splenocytes were stained for extracellular markers, as described above. After staining, cells were fixed and permeabilized with Foxp3 fixation/permeabilization buffer (Ebiosciences, San Diego, CA, USA), washed, and stained with PE-conjugated anti-Foxp3 (FJK-16 s).
Detection of cytokine-secreting T-cells
To examine IFNγ and IL-17A production, 0.5 × 10 6 RBC-depleted splenocytes were stimulated in 96-well flat bottom plates with PMA (50 ng ml − 1 , Detection of IL-10-producing B cells IL-10 production by B cells was examined under various stimulation conditions. Unless otherwise stated, 0.5 × 10 6 RBC-depleted splenocytes were plated in 96-well flat bottom plates and stimulated for 4-5 h with PMA (50 ng ml − 1 ), Ionomycin (500 ng/ml) and LPS (10 ug/ml, Sigma-Aldrich, E. coli 011:B4) in the presence of GolgiStop. Following stimulation, cells were stained with Near Infrared Live/Dead stain and various conjugated antibodies against extracellular markers, and then fixed and permeabilized, as described above. The cells were then stained with allophycocyanin-conjugated anti-IL-10(JES5-16E3) for 30 min on ice. In some experiments, the splenocytes were cultured overnight with LPS (10 μg ml − 1 ), Imiquimod (2 μM), PolyI:C (50 μg ml − 1 ), or CpG ODN 1826 (250 nM); all except LPS were purchased from InvivoGen (San Diego, CA, USA). GolgiStop was added for the last 3 h of culture and then the cells were stained and fixed as described above.
Adoptive transfers
For total B-cell adoptive transfers, red blood cell-depleted splenocytes were isolated from B6 or B6.NZBc4 mice. The cells were filtered and negatively sorted using a Pan B-cell MACs Miltenyi Isolation Column (purity routinely between 90-95%). Eight to ten million sorted B cells were transferred into 8-week-old B6.NZBc1.Th1 a IgH a recipients. Mice were bled every 2 weeks until 2 months after injections. For CD5 + adoptive transfer experiments, between 0.8-1 × 10 6 CD5 + CD19 + cells and 8-10 × 10 6 CD5 − CD19 + B cells were sorted from B6.NZBc4 mice on a FACS ARIA II and injected into 6-8-week-old B6.NZBc1 recipients. Mice were sacrificed 2 months after injection.
Autoantibody measurements
Anti-chromatin, anti-ssDNA, and anti-dsDNA IgG, IgG1 and IgG2a autoantibodies, were measured by enzyme-linked immunosorbent assay, as previously described. 3 Briefly, 96-well flat bottom plates were coated with antigen, serum was diluted and added, and bound antibodies were detected using alkaline-phosphatase conjugated anti-IgG, -IgG1 or -IgG2a secondary reagents (Southern Biotech; Birmingham, AL, USA). Substrate (4-nitrophenyl phosphate disodium salt hexahydrate, Sigma-Aldrich) was added, and the optical density of each well was measured at a wavelength of 405 nm.
Light microscopy scores
For assessment of kidney damage, kidneys were fixed in formalin, embedded in paraffin, sectioned (3 μM), and stained with periodic acid-Schiff for light microscopy. All grading was performed by a renal pathologist (GL), who was blinded to the strain of origin of the tissue section. The grading scale used for light microscopy was as follows: grade 0, normal glomeruli; grade 1, mesangial expansion, proliferation, or both; grade 2, focal and segmental (endocapillary) proliferative GN; grade 3, diffuse (endocapillary) proliferative GN; and grade 4, as 3 but with crescents.
Statistics
For comparisons of differences between three or more groups, a Kruskal-Wallis test was used followed by Dunns' post-test for multiple comparisons. When only two groups were compared, the Mann-Whiney U-test was performed unless otherwise stated. All statistical analyses were performed using GraphPad software (La Jolla, CA, USA).
